Intervention not reported
Withdrawals · patients with chronic obstructive pulmonary disease
The intervention leads to lower withdrawals (high certainty).
1 finding from 1 review
Intervention not reported
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐fatal, serious adverse pneumonia events (requiring hospital admission) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse pneumonia events (requiring hospital… (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in mortality (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
Six‐minute walk distance · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes hospital admissions due to exacerbations compared with tiotropium (very low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
1 finding from 1 review
Exacerbations requiring steroids, antibiotics or both · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in exacerbations requiring steroids, antibiotics or both compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide leads to higher quality of life Number of patients who achieved at least 4 units… compared with placebo (high certainty).
1 finding from 1 review
Six‐minute walk distance · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide leads to lower hospital admissions due to exacerbations compared with placebo (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Exacerbations requiring steroids, antibiotics or both · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes exacerbations requiring steroids, antibiotics or both compared with tiotropium (very low certainty).
1 finding from 1 review
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
All‐cause mortality · patients with managing pulmonary tuberculosis
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
Sputum Conversion by 2 months · patients with managing pulmonary tuberculosis
The intervention may leads to higher sputum Conversion by 2 months (low certainty).
1 finding from 1 review
Intervention not reported
Sputum conversion at 6 months · patients with managing pulmonary tuberculosis
The intervention showed no clear difference in sputum conversion at 6 months (moderate certainty).
1 finding from 1 review
Intervention not reported
Clinical Improvement at 1 month · patients with managing pulmonary tuberculosis
It is very uncertain whether the intervention changes clinical Improvement at 1 month (very low certainty).
1 finding from 1 review
Adverse events at study endpoint · patients with chronic obstructive pulmonary disease
Mometasone/formoterol (MF/F) showed no clear difference in adverse event—any—400/103 Duration of six months compared with placebo (low certainty).
2 findings from 1 review
OR 0.98 [0.75, 1.3]
890 participants
Low
OR 0.82 [0.62, 1.09]
894 participants
Low